trending Market Intelligence /marketintelligence/en/news-insights/trending/g3DFcjXDgw0HncxZpGOb7A2 content esgSubNav
In This List

Indivior gets US FDA approval for opioid use treatment Sublocade

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Indivior gets US FDA approval for opioid use treatment Sublocade

The U.S. Food and Drug Administration approved Indivior PLC's Sublocade, a medication-assisted treatment option for moderate-to-severe opioid use disorder.

Sublocade, or extended-release buprenorphine, is a once-monthly injectable that can be used by adult patients who have initiated treatment with a transmucosal buprenorphine-containing product.

Sublocade was evaluated in two clinical trials, with results showing it fully blocked the drug-liking effects of opioid pain medication hydromorphone, and was shown to be superior to placebo in achieving more illicit opioid-free weeks, respectively.

The FDA is requiring postmarketing studies evaluating Sublocade in higher doses, without a stable dose of buprenorphine and at dose intervals longer than once-monthly. Indivior was also asked to determine a process for transitioning patients from buprenorphine to Sublocade without a loading dose.

The company expects to launch the drug in the U.S. in the first quarter of 2018.